Ganciclovir ophthalmic

Drug Profile

Ganciclovir ophthalmic

Alternative Names: Ganciclovir ophthalmic gel 0.15%; ST-605; Virgan; Zirgan

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Laboratoires Thea
  • Developer Laboratoires Thea; Ms Science; Sirion Therapeutics
  • Class Antineoplastics; Antivirals; Hypoxanthines; Small molecules
  • Mechanism of Action DNA-directed DNA polymerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Ocular herpes simplex
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Ocular herpes simplex
  • Phase II Cytomegalovirus infections

Most Recent Events

  • 31 Mar 2017 Ms Science Corporation completes a phase II trial for Cytomegalovirus infections (in patients with cytomegalovirus corneal endotheliitis) in Japan (Ophthalmic) (JapicCTI-163186)
  • 21 Jan 2016 Phase-II clinical trials in Cytomegalovirus infections in Japan (Ophthalmic) before January 2016 (Ms Science Corporation pipeline, January 2016)
  • 26 Apr 2010 Launched for Ocular herpes simplex (acute herpetic keratitis) in USA (Ophthalmic)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top